we now have our own CD19 CAR T, which is allogenic, and so it looks like we are keeping it all in-house. I think this talks to Yuman's confidence on CF33 doing what it does so well that this will give Imugene more control over how we take onCARlytics to market.
Remember, Yuman referenced "our solid to liquid program" in the March roadshow? the little hints were there.....
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-30
-
- There are more pages in this discussion • 477 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |